Myriad Genetics
Brief History
Founded in 1991, Myriad was one of the first genomic companies, driven by the vision of elucidating the role genes play in human disease and using this critical information to improve patient care by developing novel molecular diagnostic products.
molecular diagnostic products
Myriad’s molecular diagnostic products are designed to assess an individual's risk for developing disease so that action can be taken to prevent or delay its onset.
diagnostic tests
Our diagnostic tests help in the early and accurate diagnosis of disease, when it is more treatable and survival rates are better.
prognostic medicine products
Our prognostic medicine products assess a patient's risk of disease progression and recurrence, so that a healthcare professional knows how aggressively to treat the disease.
companion diagnostic products
Our companion diagnostic products identify a patient’s likelihood of responding to a particular therapy to ensure optimal treatment decisions.
